Sho Kurihara1, Yuka Ueda1, Yoshiyuki Onitake1, Taijiro Sueda1, Emi Ohta2, Nagisa Morihara2, Shoko Hirano2, Fumiko Irisuna2, Eiso Hiyama3. 1. Department of Pediatric Surgery, Hiroshima University Hospital, Hiroshima 734-8551 Japan. 2. Natural Science Center for Basic Research and Development (N-BARD), Hiroshima University, Hiroshima, Japan. 3. Department of Pediatric Surgery, Hiroshima University Hospital, Hiroshima 734-8551 Japan; Natural Science Center for Basic Research and Development (N-BARD), Hiroshima University, Hiroshima, Japan. Electronic address: eiso@hiroshima-u.ac.jp.
Abstract
PURPOSE: Our aims are to determine circulating free DNA (cfDNA) in childhood solid tumor patients who underwent surgical intervention and to analyze any relationships with clinical parameters. METHODS: Fourty-four consenting children admitted with solid tumors between 2010 and 2014 were recruited. CfDNAs isolated from 0.5mL plasma obtained before and 1-30days after surgery were analyzed by next-generation sequencing (NGS: IonTorrent Cancer Hotspot panel) and by gene amplification analysis using a digital PCR (dPCR) platform. RESULTS: Total amounts of cfDNA were 54-825ng and were significantly associated with stage of disease. In cfDNA, 15 mutations or deletions (2 ALK, 2 TP53, 1 WT1, 3 CTNNB1, 1 APC, 1 KIT, 1 RET, 1 CDNK2AT, and 3 SMARCB1) were identified. In 10 neuroblastoma suspected cases, 2 showed high copy numbers of MYCN using dPCR. The positive rate in our cohort was 36%, and all of these aberrations were detected in the original tumors. None of the aberrations were detectable in cfDNA after surgery except for three cases whose tumors remained after surgery. CONCLUSIONS: These data demonstrate the feasibility and potential utility of mutation/deletion/amplification screening in cfDNA using NGS and dPCR for the detection of tumor biomarkers in children with solid tumors. These markers also have the potential utility to evaluate complete resection after surgery.
PURPOSE: Our aims are to determine circulating free DNA (cfDNA) in childhood solid tumorpatients who underwent surgical intervention and to analyze any relationships with clinical parameters. METHODS: Fourty-four consenting children admitted with solid tumors between 2010 and 2014 were recruited. CfDNAs isolated from 0.5mL plasma obtained before and 1-30days after surgery were analyzed by next-generation sequencing (NGS: IonTorrent Cancer Hotspot panel) and by gene amplification analysis using a digital PCR (dPCR) platform. RESULTS: Total amounts of cfDNA were 54-825ng and were significantly associated with stage of disease. In cfDNA, 15 mutations or deletions (2 ALK, 2 TP53, 1 WT1, 3 CTNNB1, 1 APC, 1 KIT, 1 RET, 1 CDNK2AT, and 3 SMARCB1) were identified. In 10 neuroblastoma suspected cases, 2 showed high copy numbers of MYCN using dPCR. The positive rate in our cohort was 36%, and all of these aberrations were detected in the original tumors. None of the aberrations were detectable in cfDNA after surgery except for three cases whose tumors remained after surgery. CONCLUSIONS: These data demonstrate the feasibility and potential utility of mutation/deletion/amplification screening in cfDNA using NGS and dPCR for the detection of tumor biomarkers in children with solid tumors. These markers also have the potential utility to evaluate complete resection after surgery.
Authors: Rajen J Mody; John R Prensner; Jessica Everett; D Williams Parsons; Arul M Chinnaiyan Journal: Pediatr Blood Cancer Date: 2016-10-17 Impact factor: 3.167
Authors: Bruce M Wollison; Edwin Thai; Aimee Mckinney; Abigail Ward; Andrea Clapp; Catherine Clinton; Anwesha Nag; Aaron R Thorner; Julie M Gastier-Foster; Brian D Crompton Journal: PLoS One Date: 2017-12-05 Impact factor: 3.240
Authors: Rick Kamps; Rita D Brandão; Bianca J van den Bosch; Aimee D C Paulussen; Sofia Xanthoulea; Marinus J Blok; Andrea Romano Journal: Int J Mol Sci Date: 2017-01-31 Impact factor: 5.923
Authors: Ian A Cree; Lesley Uttley; Helen Buckley Woods; Hugh Kikuchi; Anne Reiman; Susan Harnan; Becky L Whiteman; Sian Taylor Philips; Michael Messenger; Angela Cox; Dawn Teare; Orla Sheils; Jacqui Shaw Journal: BMC Cancer Date: 2017-10-23 Impact factor: 4.430